HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Amorfix enters into agreement with a major global pharmaceutical company for Alzheimer's disease diagnostic
Amorfix Life Sciences Ltd., an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases, has signed an agreement with a major global pharmaceutical company to use the human Alzheimer's disease diagnostic assay in phase 1 clinical studies.

Amorfix has granted its collaborator access to its proprietary EP-AD assay technology and the Company will complete assay optimization and validation prior to using the assay as part of a clinical trial to investigate the effects of a novel therapeutic for the treatment of Alzheimer's disease. The terms of the agreement have not been disclosed.

"We are very excited to be working with a world-class pharmaceutical company with the resources and expertise to assist in the further development our human Alzheimer's disease diagnostic assay technology. The Company has worked very hard to create a diagnostic test that can identify patients with early-stage disease and we are gratified to have the opportunity to assist in the clinical development of new therapeutics that may offer improved treatment options for Alzheimer's disease patients" said Dr. Robert Gundel, Amorfix President and CEO. "In addition, this agreement is an example of our business plan to establish effective partnerships and strategic alliances with companies that have the resources and expertise to help advance our products to clinical development and commercialization".

The EP-AD diagnostic assay is capable of identifying early-stage Alzheimer's disease patients and patients with mild cognitive impairment (MCI) who are at high risk of developing Alzheimer's disease. The EP-AD assay measures levels of Abeta aggregates, a known biomarker of Alzheimer's disease, and can also be used to monitor the effects of Alzheimer's disease treatments on Abeta aggregates, the building blocks of plaques that form in the brains of people with Alzheimer's disease.
information, future events or otherwise.

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy